The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1049
March 26, 1999
View Complete Issue         Table of Contents 2019 
Valrubicin for Bladder Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Valrubicin for Bladder Cancer
March 26, 1999 (Issue: 1049)
Valrubicin (Valstar), formerly known as AD 32, has been approved by the FDA for intravesical treament of bladder cancer. The approval is limited to patients with carcinoma-in-situ refractory to BCG for whom immediate cystectomy is contraindicated.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Valrubicin for Bladder Cancer
Article code: 1049c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.